Menu Search
Equities

Ocumension Therapeutics

5DG:FRA

Ocumension Therapeutics

Actions
  • Price (EUR)0.52
  • Today's Change0.02 / 4.00%
  • Shares traded1.00k
  • 1 Year change-38.10%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Ocumension Therapeutics grew revenues 54.99% from 158.96m to 246.37m while net income improved from a loss of 402.64m to a smaller loss of 379.79m.
Gross margin58.29%
Net profit margin-104.01%
Operating margin-103.06%
Return on assets-10.71%
Return on equity-11.71%
Return on investment-11.55%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Ocumension Therapeutics fell by 327.21m. Cash Flow from Financing totalled 108.66m or 44.10% of revenues. In addition the company used 177.93m for operations while cash used for investing totalled 259.78m.
Cash flow per share-0.4342
Price/Cash flow per share--
Book value per share4.39
Tangible book value per share2.49
More ▼

Balance sheet in CNYView more

Ocumension Therapeutics appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio5.35
Quick ratio5.00
Total debt/total equity0.0055
Total debt/total capital0.0055
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.